Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01082874 · ClinicalTrials.gov registry record · Phase 3
PeriOperative ISchemic Evaluation-2 Trial
A Phase 3 study of Cardiovascular Disease, sponsored by Hamilton Health Sciences Corporation.
- Completed
- Registry status
- Phase 3
- Development phase
- 10,010
- Enrollment target
- 20
- Study locations
NCT01082874: Completed Phase 3 study of Cardiovascular Disease, sponsored by Hamilton Health Sciences Corporation.
NCT01082874 is a Phase 3 study of Cardiovascular Disease that has completed, run by Hamilton Health Sciences Corporation. The registered enrollment target is 10,010 participants, above the 2,624-participant average among 137 other Cardiovascular Disease trials with a reported enrollment target (281% higher). The trial reports 20 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01082874, a Phase 3 study of Cardiovascular Disease, has completed, sponsored by Hamilton Health Sciences Corporation.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 10,010 participants
- Enrollment target
- 20
- Study locations
Study Summary
Major surgeries not involving the heart are common, and major heart problems during or after such surgeries represent a large population health problem. Few treatments to prevent heart problems around the time of surgery have been tested. There is encouraging data suggesting that small doses of Acetyl-Salicylic Acid (ASA) and Clonidine, which are two medications, given individually for a short period before and after major surgeries may prevent major heart problems. The POISE-2 Trial is a large international study to test if ASA and Clonidine can prevent heart attacks and deaths from heart problems around the time of surgery.
Conditions Studied
Interventions
- DRUG Active Clonidine
- DRUG Placebo Clonidine
- DRUG Active ASA
- DRUG Placebo ASA
Study Locations (20)
Other
- National Coordination Office - Rosario
- National Coordination Office - Vienna
- National Coordination Office - Brussels
- National Coordination Office - São Paulo
- National Coordination Office - Santiago
- National Coordination Office - Bucamaranga
- National Coordination Office - Herlev
- National Coordination Office - Boulogne-Billancourt
- National Coordination Office - Bonn
- National Coordination Office - Hong Kong
- National Coordination Office - Bangalore
- National Coordination Office - Milan
- National Coordination Office - Kuala Lumpur
- National Coordination Office - Auckland
- National Coordination Office - Islamabad
- National Coordination Office - Lima
- National Coordination Office - Durban
Ohio
- National Coordination Office - Cleveland
Victoria
- National Coordination Office Australia and New Zealand - Parkville
Ontario
- National Coordination Office - Hamilton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10,010 participants |
| Start Date | 2010-07 |
| Est. Completion | 2015-01 |
| Phase | Phase 3 |
What the finished NCT01082874 record still lists
NCT01082874 is an interventional study that assigns participants to a tested intervention. Its 10,010 participants enrollment target places it among the larger protocols in the corpus, above the 2,624-participant average among 137 other Cardiovascular Disease trials with a reported enrollment target (281% higher).
The record links to 1 condition, with Cardiovascular Disease appearing as the primary indexed condition, and to 4 interventions - of which Active Clonidine is the first listed.
NCT01082874 names 20 study sites across 4 states, led by Other, Ohio, Victoria.
Frequently Asked Questions
What is clinical trial NCT01082874 about?
NCT01082874 is a clinical study titled "PeriOperative ISchemic Evaluation-2 Trial". Major surgeries not involving the heart are common, and major heart problems during or after such surgeries represent a large population health problem. Few treatments to prevent heart problems around the time of surgery have been tested. There is encouraging data suggesting that small doses of Acet...
What is the current status of trial NCT01082874?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 10,010 participants. The study started on 2010-07. Estimated completion is 2015-01.
What conditions does trial NCT01082874 study?
This clinical trial studies the following conditions: Cardiovascular Disease.
What interventions are being tested in trial NCT01082874?
The interventions under investigation include: Active Clonidine (DRUG), Placebo Clonidine (DRUG), Active ASA (DRUG), Placebo ASA (DRUG).
Who is sponsoring clinical trial NCT01082874?
This trial is sponsored by Hamilton Health Sciences Corporation, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01082874 being conducted?
This trial has 20 study locations across Ohio, Victoria, Ontario. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cardiovascular Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01082874's enrollment target sits among peer trials
10,010 10th of 137 higher than 128 of 137 other Cardiovascular Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cardiovascular Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event
RECRUITING · Phase 3
-
OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events
RECRUITING · Phase 3
-
VITAL Rhythm Study
ACTIVE NOT RECRUITING · Phase 3
-
A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With Clinical ASCVD or at Risk for a First ASCVD Event
ACTIVE NOT RECRUITING · Phase 3
-
Vitamin D and Omega-3 Trial (VITAL)
ACTIVE NOT RECRUITING · Phase 3
-
REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00160771 · 10,000 participants
Biomechanics/Motion Analysis Laboratory Data Bank
- NCT00896935 · 10,000 participants
Arizona Cancer Center Biospecimen Repository
- NCT00898235 · 10,000 participants
Collection of Samples and Clinical Data From Patients With Amyloid Diseases
- NCT00992303 · 10,000 participants
Collecting Tissue Samples From Patients With Cancer Undergoing Radiation Therapy and Healthy Participants
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia